By using GRADE system we updated the guidelines for management of CLL issued in 2006 from SIE, SIES and GITMO group. We recommended fludarabine, cyclophosphamide, rituximab (FCR) in younger and selected older patients with a good fitness status, no unfavourable genetics (deletion 17p and/or p53 mutations), and a less toxic treatment in nonfit and elderly patients. In patients without unfavourable genetics, relapsed after 24 months the same initial treatment including rituximab can be considered. In patients with unfavourable genetics, refractory or relapsed within 24 months from a prior fludarabine-based treatment, allogeneic SCT or experimental treatments should be given. (C) 2011 Elsevier Ltd. All rights reserved.
SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia / Mauro, Francesca Romana; Giuseppe, Bandini; Giovanni, Barosi; Atto, Billio; Maura, Brugiatelli; Antonio, Cuneo; Francesco, Lauria; Vincenzo, Liso; Monia, Marchetti; Meloni, Giovanna; Marco, Montillo; Pierluigi, Zinzani; Sante, Tura. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - STAMPA. - 36:4(2012), pp. 459-466. [10.1016/j.leukres.2011.08.013]
SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia
MAURO, Francesca Romana;MELONI, Giovanna;
2012
Abstract
By using GRADE system we updated the guidelines for management of CLL issued in 2006 from SIE, SIES and GITMO group. We recommended fludarabine, cyclophosphamide, rituximab (FCR) in younger and selected older patients with a good fitness status, no unfavourable genetics (deletion 17p and/or p53 mutations), and a less toxic treatment in nonfit and elderly patients. In patients without unfavourable genetics, relapsed after 24 months the same initial treatment including rituximab can be considered. In patients with unfavourable genetics, refractory or relapsed within 24 months from a prior fludarabine-based treatment, allogeneic SCT or experimental treatments should be given. (C) 2011 Elsevier Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
